Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus

Academic Appointments

Emeritus Faculty - University Medical Line, Pediatrics - Hematology & Oncology
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute

Current Research and Scholarly Interests

Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

Clinical Trials

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients Not Recruiting
More
This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant chemotherapy works in treating young patients who are undergoing surgical resection for high-risk hepatoblastoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6507251662.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia Not Recruiting
More
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining PSC-833 with chemotherapy may reduce resistance to the drug and allow more cancer cells to be killed.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Not Recruiting
More
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Not Recruiting
More
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.

Stanford is currently not accepting patients for this trial. For more information, please contact Norman J Lacayo, 650-723-5535.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Not Recruiting
More
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating children or young adults with B acute lymphoblastic leukemia.

Stanford is currently not accepting patients for this trial. For more information, please contact Christin New, 650-497-8815.
Lead Sponsor
Stanford Investigators
View full details
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Not Recruiting
More
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Not Recruiting
More
This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or relapsed/refractory lymphoblastic lymphoma. A safety expansion cohort of approximately 20 patients may be enrolled in addition to the 50 participants in dose-escalation cohort.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Not Recruiting
More
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.

Stanford is currently not accepting patients for this trial. For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis Not Recruiting
More
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.

Lead Sponsor
- Stanford University
Stanford Investigators
- Gary Dahl
View full details
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes Not Recruiting
More
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Not Recruiting
More
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Isotretinoin may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may be an effective treatment for cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Min Wang, 6507364281.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. Not Recruiting
More
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. The purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with ALL.

Stanford is currently not accepting patients for this trial. For more information, please contact Min Wang, 6507364281.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Not Recruiting
More
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every week for up to six courses. Patients are not required to be hospitalized for the administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in treating patients with recurrent or refractory solid tumors or CNS tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Not Recruiting
More
This phase I trial is studying the side effects and best dose of dasatinib in treating young patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myelogenous leukemia that did not respond to imatinib mesylate. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Stanford is currently not accepting patients for this trial. For more information, please contact Neyssa Marina, 6507235535.
Lead Sponsor
Stanford Investigators
- Gary Dahl
- Neyssa Marina
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Pediatrics
  PEDS 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience
  PEDS 280 (Aut, Win, Spr, Sum)
- Graduate Research
  PEDS 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PEDS 370 (Aut, Win, Spr, Sum)
- Undergraduate Directed Reading/Research
  PEDS 199 (Aut, Win, Spr, Sum)

Graduate and Fellowship Programs

Pediatric Hem/Onc (Fellowship Program)

All Publications

Profiles With Related Publications

close
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma
Clinical Focus
Cancer > Lymphoma, Burkitt's Lymphoma, Hodgkin's Disease, Investigational Therapeutics, Lymphoma , Mycosis Fungoides, Non-Hodgkin's Lymphoma, Oncology (Cancer), Plasmacytoma, Waldenstrom's Macroglobulinemia , Medical Oncology
Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

696 Total Publications
close
Rajni Agarwal

Professor of Pediatrics (Stem Cell Transplantation)
Clinical Focus
Blood and Marrow Transplantation, Pediatric, Cell and Gene therapy, Pediatric Hematology-Oncology
Research Interests
Hematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.
Clinical research interests are to develop new protocols to reduce Toxicity from the conditioning regimens for stem cell transplants, reducing graft vs host disease, treatment of viral infections post transplant and use of manipulated HSC graft in patients who receive haplo donor transplants.

92 Total Publications
close
Ash A. Alizadeh, MD/PhD

Moghadam Family Professor
Clinical Focus
Cancer > Lymphoma, Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, Follicular Lymphoma, Diffuse Large-Cell Lymphomas, Leukemia, Hairy Cell, Lymphoma, B-Cell, Marginal Zone, Hodgkin Disease, Medical Oncology
Research Interests
My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

445 Total Publications
close
Michael Amylon

Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Research Interests
Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.

106 Total Publications
close
Caroline Berube

Clinical Professor, Medicine - Hematology
Clinical Focus
Hemostasis Thrombosis, Anticoagulation, Pregnancy-related hematologic conditions, Hematology, Idiopathic thrombocytopenic purpura, Anemia

28 Total Publications
close
Sarah S. Donaldson, MD

Catharine and Howard Avery Professor in the School of Medicine, Emerita
Research Interests
Combined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases

312 Total Publications
close
Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Clinical Focus
Cancer > Neuro Oncology, Neurology - Child Neurology, Neuro-Oncology, Neurology
Research Interests
Clinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.

359 Total Publications
close
Andrew Gentles

Associate Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science

121 Total Publications
close
Bertil Glader

Stanford Medicine Professor of Pediatric Hematology/Oncology and Professor, by courtesy, of Pathology
Clinical Focus
Pediatric Hematology-Oncology
Research Interests
Hematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.

262 Total Publications
close
Peter Greenberg

Professor of Medicine (Hematology), Emeritus
Clinical Focus
Cancer > Hematology, Hematology, Myelodysplastic Syndromes

345 Total Publications
close
Richard Hoppe

Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Clinical Focus
Cancer > Lymphoma, Cancer > Radiation Oncology, Lymphoma , Cutaneous Lymphoma , Cutaneous Lymphoma - Radiation Oncology, Hodgkin's Disease - Radiation Oncology, Non-Hodgkin's Lymphoma - Radiation Oncology, Mycosis Fungoides - Radiation Oncology, Burkitt's Lymphoma - Radiation Oncology, Burkitt's Lymphoma, Leukemia, Leukemia - Radiation Oncology, Plasmacytoma, Plasmacytoma - Radiation Oncology, Radiation Oncology
Research Interests
Irradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.

367 Total Publications
close
Norman J. Lacayo, MD

Associate Professor of Pediatrics (Hematology and Oncology)
Clinical Focus
Hematology/Oncology/Stem Cell Transplant, Pediatric, Oncology (Cancer), Pediatric, AML, childhood and adolescent/young adult, ALL, childhood and adolescent/young adult, lymphoblastic lymphoma, childhood, Pediatric Hematology-Oncology
Research Interests
Pediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.

115 Total Publications

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

2023-24 Courses

Graduate and Fellowship Programs

Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Rajni Agarwal

Professor of Pediatrics (Stem Cell Transplantation)

Ash A. Alizadeh, MD/PhD

Moghadam Family Professor

Michael Amylon

Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus

Caroline Berube

Clinical Professor, Medicine - Hematology

Sarah S. Donaldson, MD

Catharine and Howard Avery Professor in the School of Medicine, Emerita

Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health

Andrew Gentles

Associate Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science

Bertil Glader

Stanford Medicine Professor of Pediatric Hematology/Oncology and Professor, by courtesy, of Pathology

Peter Greenberg

Professor of Medicine (Hematology), Emeritus

Richard Hoppe

Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology

Norman J. Lacayo, MD

Associate Professor of Pediatrics (Hematology and Oncology)